Trial Profile
A Phase 1, Dose-escalating Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of AD-214 When Administered Intravenously to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs AD-214 (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Adverse reactions; First in man
- Sponsors AdAlta
- 02 Nov 2023 According to an AdAlta media release, company has launched a placement to sophisticated and professional investors to raise up to A$1.23 million at an issue price of 2 cents per new share, with funds to go towards the completion of analysis of Phase 1 extension clinical study of AD-214 and to progress ongoing partnering discussions.
- 20 Jul 2023 According to an AdAlta media release, Dr Tim Oldham spoke to Bulls N Bears Matt Birney on the development of its i-body platform technology, and more specifically, progress for lead product AD-214, for the treatment of fibrotic diseases including Idiopathic Pulmonary Fibrosis (IPF).
- 06 Jul 2023 According to an AdAlta media release, AD-214 favourably links preclinical animal studies and Phase I human trial results, providing important dose frequency insights as it moves through the clinic.The findings de-risk the I-body candidates future move into Phase 2 clinical trials and stand to boost confidence as AdAlta progresses partnership discussions.